OTCMKTS:IMUC EOM Pharmaceuticals (IMUC) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free IMUC Stock Alerts $0.20 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.20▼$0.2050-Day Range$0.11▼$0.3052-Week Range$0.11▼$0.40VolumeN/AAverage Volume3,338 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get EOM Pharmaceuticals alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About EOM Pharmaceuticals Stock (OTCMKTS:IMUC)Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.Read More IMUC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMUC Stock News HeadlinesApril 19, 2024 | americanbankingnews.comEOM Pharmaceuticals (OTCMKTS:IMUC) Shares Up 17.3%January 5, 2024 | uk.finance.yahoo.comImmunoCellular Therapeutics, Ltd. (IMUC)April 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.December 29, 2023 | wsj.comEOM Pharmaceutical Holdings Inc.November 7, 2023 | finance.yahoo.comEOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613November 4, 2023 | markets.businessinsider.comIZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 YearsNovember 3, 2023 | msn.comImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives RevenuesNovember 1, 2023 | morningstar.comOramed Pharmaceuticals Inc ORMPApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.October 11, 2023 | markets.businessinsider.comAnalyst Ratings for Olema PharmaceuticalsSeptember 6, 2023 | finance.yahoo.comEOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in BrazilAugust 17, 2023 | uk.finance.yahoo.comQ2 2023 PAVmed Inc Earnings CallAugust 3, 2023 | msn.comEOM Pharmaceuticals shelves plans to uplist shares, raise $15MJuly 17, 2023 | benzinga.comAcumen Pharmaceuticals Announces Proposed Public Offering of Common StockJuly 3, 2023 | marketwatch.comAmneal Pharmaceuticals: FDA Requests Additional Information on IPX203 IngredientJune 14, 2023 | marketwatch.comAmneal Pharmaceuticals Gets FDA Approval for Injectable Tumor TreatmentMay 16, 2023 | msn.comTrade commission fights Amgen's $28B purchase of Horizon TherapeuticsMay 10, 2023 | msn.comPharma CEOs to testify in U.S. Senate hearing on insulin pricesMay 10, 2023 | marketwatch.com8-K: Acumen Pharmaceuticals, Inc.May 9, 2023 | msn.comOlema Pharmaceuticals GAAP EPS of -$0.70 misses by $0.04May 9, 2023 | investing.comOliX Pharmaceuticals Inc (226950)March 30, 2023 | msn.comUSFDA gives final nod to Alembic Pharmaceuticals’ Glaucoma drugMarch 27, 2023 | reuters.comU.S. Supreme Court mulls Amgen bid to revive cholesterol drug patentsMarch 13, 2023 | marketwatch.comRegeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gainsMarch 11, 2023 | finance.yahoo.comEOM Pharmaceuticals Holdings, Inc. (IMUC)February 24, 2023 | seekingalpha.comIonis Pharmaceuticals, Inc. (IONS) Q4 2022 Earnings Call TranscriptDecember 8, 2022 | technews.tmcnet.comAltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological DiseasesSee More Headlines Receive IMUC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EOM Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2018Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:IMUC CUSIPN/A CIK822411 Webwww.imuc.com Phone(201) 351-0605Fax818-224-5287Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.37 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Irach B. Taraporewala B.S. (Age 68)M.S., Ph.D., CEO, President & Director Comp: $265.65kMr. Wayne I. Danson CPA (Age 70)CFO & Treasurer Comp: $150kMr. Eli Goldberger (Age 34)Founder, Chairman & COO Dr. Shalom Z. Hirschman M.D. (Age 88)Co-Founder, Chief Scientific Officer & Medical Director Key CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors IMUC Stock Analysis - Frequently Asked Questions How have IMUC shares performed in 2024? EOM Pharmaceuticals' stock was trading at $0.2320 at the start of the year. Since then, IMUC stock has decreased by 14.7% and is now trading at $0.1979. View the best growth stocks for 2024 here. Are investors shorting EOM Pharmaceuticals? EOM Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 400 shares, an increase of 300.0% from the March 31st total of 100 shares. Based on an average trading volume of 7,500 shares, the days-to-cover ratio is currently 0.1 days. View EOM Pharmaceuticals' Short Interest. How were EOM Pharmaceuticals' earnings last quarter? EOM Pharmaceuticals Holdings, Inc. (OTCMKTS:IMUC) posted its earnings results on Monday, August, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter. How do I buy shares of EOM Pharmaceuticals? Shares of IMUC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IMUC) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EOM Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
